Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 4/20 | 0.49 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140925 | 0.84 | CNR1 (0.43) | NAAAHTTEPHX2ASAH1 | |
| SCHEMBL9508710 | 0.83 | ALDH1A1 (0.50) | NAAANAMPTEPHX1ALDH1A1HTT | |
| SCHEMBL4137692 | 0.83 | EPHX2 (0.52) | NAAANAMPTEPHX1ALDH1A1HTT | |
| SCHEMBL3200016 | 0.81 | NAAA (0.50) | NAAANAMPTEPHX1ALDH1A1HTT | |
| SCHEMBL4137357 | 0.80 | NAAA (0.58) | NAAANAMPTEPHX1ALDH1A1HTT | |
| SCHEMBL5268847 | 0.80 | NAAA (0.48) | NAAAEPHX1ALDH1A1HTTNPC1 | |
| SCHEMBL4128007 | 0.78 | CES2 (0.43) | ALDH1A1HTTEPHX2ASAH1 | |
| SCHEMBL4141687 | 0.77 | HDAC11 (0.45) | NAAAEPHX1ALDH1A1HTTNPC1 | |
| SCHEMBL7469022 | 0.76 | NAMPT (0.43) | NAAANAMPTEPHX1ALDH1A1HTT | |
| SCHEMBL2318009 | 0.76 | KDM4E (0.35) | ALDH1A1NPC1RAB9AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| WO-2009077844-A2 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | QUONOVA LLC (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | PGLS, TFPI, Q6ZSR9 | NAAA 213/4885NAMPT 1434/4885EPHX1 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.